Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596451 · ClinicalTrials.gov registry record · Phase 3
To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).
A Phase 3 study of Osteoarthritis, sponsored by Glenmark Pharmaceuticals Ltd. India.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,164
- Enrollment target
- 20
- Study locations
NCT02596451 is a Phase 3 study of Osteoarthritis that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 1,164 participants, above the 809-participant average among 135 other Osteoarthritis trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02596451, a Phase 3 study of Osteoarthritis, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,164 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium topical gel) 1% (Novartis Consumer Health, Inc) in Patients with Osteoarthritis (OA) of the Knee
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Diclofenac Sodium gel, 1%
- DRUG Voltaren® Gel
Study Locations (20)
California
- Glenmark Investigational Site 1 - Anaheim
- Glenmark Investigational Site 21 - Anaheim
- Glenmark Investigational Site 31 - Anaheim
- Glenmark Investigational Site 26 - Canoga Park
- Glenmark Investigational Site 42 - Carlsbad
- Glenmark Investigational Site 30 - Carmichael
- Glenmark Investigational Site 33 - Cerritos
- Glenmark Investigational Site 25 - El Cajon
- Glenmark Investigational Site 24 - La Mesa
- Glenmark Investigational Site 2 - Pasadena
- Glenmark Investigational Site 13 - Rancho Cucamonga
- Glenmark Investigational Site 27 - Sacramento
Florida
- Glenmark Investigational Site 10 - Fort Lauderdale
- Glenmark Investigational Site 41 - Hialeah
- Glenmark Investigational Site 15 - Miami
- Glenmark Investigational Site 19 - Miami
- Glenmark Investigational Site 28 - Miami
- Glenmark Investigational Site 32 - Miami
- Glenmark Investigational Site 40 - Miami
Arizona
- Glenmark Investigational Site 5 - Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,164 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02596451
The ClinicalTrials.gov registry entry for NCT02596451 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,164 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 809-participant average among 135 other Osteoarthritis trials with a reported enrollment target (44% higher). The listed sponsor is Glenmark Pharmaceuticals Ltd. India, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02596451 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02596451 about?
NCT02596451 is a clinical study titled "To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).". This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium topical gel) 1% (Novartis Consumer Health, Inc) in Patients wi...
What is the current status of trial NCT02596451?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,164 participants. The study started on 2015-08. Estimated completion is 2016-03.
What conditions does trial NCT02596451 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT02596451?
The interventions under investigation include: Placebo (DRUG), Diclofenac Sodium gel, 1% (DRUG), Voltaren® Gel (DRUG).
Who is sponsoring clinical trial NCT02596451?
This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02596451 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.